A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
The Hutchmed-originated savolitinib moves towards its first US approval.
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.